the next great thing is already here, page-69

A healthy debate indeed surges.

My first question in whether a capital raising for one company which is then used in part to finance another company even legal? I've never come across such a scenario before and in my mind its one that does not seem logical at all. Companies on the asx frequently go bust and even more frequently in the biotech sector so its up to the shareholders to conduct their due diligence and pick the right company. No matter how closely related our management team are to any other company that does not give them any right to use shareholders funds to finance another operation other than OBJ?

Secondly why have OBJ never announced a OBJ/PNO collaboration? They have never been talked about nor alluded to so i'm still confused as to the connection.

Lastly i don't think we should take into consideration the rise from 1.1cents as IMO that was an outlier when the shareholders were at their extremes emotionally. IMO 2cents and 1.8cents are long term supports and neutral points for OBJ in extended silences. Are we simply consolidating?

I'm trying to wrap my head around a CR at this moment in time, there is so much going on in the background that might act as a catalyst for the SP to explode that IMO pulling the trigger now is premature. I would rather wait for the updates from GSK and P&G before considering a CR. But at the end of the day as you said, management don't need our permission as it was already granted.


Coppertop01, i agree with your observation. 0.02 has been sold into quite heavily for the past week.